Compare Revvity Inc (RVTY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Thomson Reuters Corp — how do they compare? Revvity Inc trades at $114.99 (market cap $12.91B), while Thomson Reuters Corp trades at $101.45 (market cap $45.38B). The key difference: Thomson Reuters Corp is far larger — about 3.5× Revvity Inc's market cap, and Thomson Reuters Corp pays the higher dividend (2.5%). Which is the better fit depends on your goals.
| RVTY | TRI | |
|---|---|---|
Market Cap | $12.91B | $45.38B |
Sector | Technology | Industrials |
52-Week High | $117.75 | $178.77 |
52-Week Low | $82.26 | $76.55 |
Enterprise Value | $15.23B | $48.00B |
Dividend Yield | 0.24% | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
Thomson Reuters (TRI) trades at $104.36, up 2.48% today, with a bullish technical signal and strong support at $102. The company reported Q2 2026 earnings of $0.99 per share, beating estimates, and raised full-year revenue guidance. Fundamentals show robust profitability with a 21.22% net income margin and 8% organic revenue growth, though cash flow trends indicate recent net outflows.
Outlook remains positive driven by AI product adoption and recurring revenue growth, but risks include execution on tech transitions and competitive pressures. Analysts project a 29.8% upside to the $124 high target, with a majority recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
